Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02282020
Recruitment Status : Active, not recruiting
First Posted : November 4, 2014
Results First Posted : December 2, 2019
Last Update Posted : December 2, 2019
Sponsor:
Collaborators:
Myriad Genetic Laboratories, Inc.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at least 6 months after the last platinum based chemotherapy. Patient should have received at least 2 prior lines of platinum based chemotherapy. The aim of the study is to assess the efficacy and safety of olaparib tablets.

Condition or disease Intervention/treatment Phase
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity Drug: OLAPARIB Drug: Single agent chemotherapy Phase 3

Expanded Access : An investigational treatment associated with this study has been approved for sale to the public.   More info ...

Detailed Description:
This open label, randomised, controlled, multi-centre study will assess the efficacy and safety of single agent olaparib vs. standard of care, based on physician's choice of single agent chemotherapy ( i.e paclitaxel, or topotecan, or pegylated liposomal doxorubicin, or gemcitabine) in platinum sensitive or partially platinum sensitive relapsed ovarian cancer patients who carry germline deleterious or suspected deleterious BRCA mutation and who have received at least 2 prior lines of platinum based chemotherapy. Patients are eligible to undergo BRCA testing even if they have not yet had recurrence or progression of disease >6 months (>/=183 days) after completion of their last platinum therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 266 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations.
Actual Study Start Date : February 6, 2015
Actual Primary Completion Date : October 10, 2018
Estimated Study Completion Date : May 31, 2021


Arm Intervention/treatment
Experimental: 1/OLAPARIB
olaparib 300mg oral tablets; twice daily
Drug: OLAPARIB
300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.

Active Comparator: 2/CHEMOTHERAPY
Physician's choice single agent chemotherapy
Drug: Single agent chemotherapy
Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria




Primary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: Maximum of 45 Months ]

    Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria was used by a Blinded Independent Central Review (BICR) to assess participant response to treatment

    Objective Response Rate (ORR) is the number of participants with Complete Response (CR) or Partial Response (PR) in the Measurable Disease Analysis Set (MDAS). Complete response is declared when all lesions have disappeared or all lesions have disappeared and all nodal disease is < 10 mm each. Partial response is declared when there is a decrease in sum of diameters of target lesions ≥ 30%.



Secondary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: Maximum of 45 Months ]
    RECIST 1.1 criteria was used to assess participant response to treatment. PFS was defined as the time from randomization until the date of objective radiological disease progression according to RECIST 1.1 or death (by any cause in the absence of disease progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to disease progression (i.e., date of RECIST progression/death or censoring - date of randomization +1).

  2. Time From Randomisation to Second Progression (PFS2) [ Time Frame: Maximum of 45 Months ]
    Time from randomization to PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to first progression or death. The date of second progression was recorded by the investigator and defined according to local standard clinical practice, and could involve objective radiological, clinical, cancer antigen-125 (CA-125) progression or death. CA-125 progression was assessed per Gynecological Cancer Intergroup (GCIG) criteria.

  3. Overall Survival (OS) [ Time Frame: Maximum of 45 Months ]
  4. Time To Earliest Progression By RECIST 1.1 Or Cancer Antigen (CA) -125 Or Death [ Time Frame: Maximum of 45 Months ]
    Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria was used to assess participant response to treatment. CA-125 progression was assessed per Gynecological Cancer Intergroup (GCIG).

  5. Time From Randomization To First Subsequent Therapy Or Death (TFST) [ Time Frame: Maximum of 45 Months ]
    TFST was defined as the time from the date of randomization to the earlier of first subsequent therapy start date or death.

  6. Time From Randomization To Second Subsequent Therapy Or Death (TSST) [ Time Frame: Maximum of 45 Months ]
    TSST was defined as the time from the date of randomization to the earlier of second subsequent chemotherapy start date following study treatment discontinuation, or death.

  7. Time From Randomization To Study Treatment Discontinuation Or Death (TDT) [ Time Frame: Maximum of 45 Months ]
    TDT was defined as the time from randomization to the earlier of the date of study treatment discontinuation or death.

  8. Duration of Response (DoR) [ Time Frame: Maximum of 45 Months ]
    Duration of response is the time from the first documentation of complete response (CR) or partial response (PR) until the date of progression or death, or the last evaluable RECIST assessment for participants that do not progress or progress after 2 missed assessments. Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria was used to assess participant response to treatment.

  9. Time to Response (TTR) [ Time Frame: Maximum of 45 Months ]
    TTR was defined as the time from randomization until the date of first documented response by Blinded independent central review (BICR) assessment.

  10. Mean Change From Baseline In Trial Outcome Index (TOI) Score [ Time Frame: Baseline (Day 1) to Week 48 (±1 week) ]
    The TOI score was derived from the sum of the scores of the 25 items included in the physical well-being (7 items), functional well-being (7 items), and additional concerns ovarian cancer subscale (11 items) of the FACT-O questionnaire Version 4. A negative change in score from baseline indicated a worsening in symptoms.

  11. Number of Participants Who Show an Improvement in TOI Score [ Time Frame: Baseline (Day 1) to Week 48 (±1 week) ]
    The TOI score was derived from the sum of the scores of the 25 items included in the physical well-being (7 items), functional well-being (7 items), and additional concerns ovarian cancer subscale (11 items) of the FACT-O questionnaire Version 4. TOI score ranges from 0 to 100, a higher score indicates a higher health-related quality of life (HRQoL). A change in at least 10 points was considered clinically relevant.

  12. Objective Response Rate (ORR) in Breast Cancer Susceptibility (BRCA) Gene Population by Blinded Independent Central Review (BICR) [ Time Frame: Maximum of 45 Months ]

    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis).

    The number of participants with complete or partial response per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria. Partial response is declared when there is a decrease in sum of target disease ≥ 30%. Complete response is declared when all lesions have disappeared or all lesions have disappeared and all nodal disease is < 10 mm each.


  13. Number of Participants Who Experienced Disease Progression or Death in BRCA Gene Population by Blinded Independent Central Review (BICR) [ Time Frame: Maximum of 45 Months ]

    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis).

    Progressive disease was defined as at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.


  14. Number of Participants Who Experienced Second Progression or Death (PFS2) in BRCA Gene Population [ Time Frame: Maximum of 45 Months ]
    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis).

  15. Overall Survival (OS) in BRCA Gene Population [ Time Frame: Maximum of 45 Months ]

    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis).

    OS in BRCA gene population was measured by the number of participants who died due to any cause.


  16. Number of Participants Who Discontinued Study Treatment or Died in BRCA Gene Population [ Time Frame: Maximum of 45 Months ]
    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis).

  17. Number of Participants Who Received Subsequent Chemotherapy or Died in BRCA Gene Population [ Time Frame: Maximum of 45 Months ]
    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis).

  18. Number of Participants Who Received Second Subsequent Chemotherapy or Died in BRCA Gene Population [ Time Frame: Maximum of 45 Months ]
    BRCA gene population includes participants identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (eg, gene sequencing and large rearrangement analysis).

  19. Geometric Mean Plasma Concentration of Olaparib [ Time Frame: Day 1, 1 hour post-dose and Day 29 pre-dose ]
  20. Number of Participants Who Experience at Least One Adverse Event (AE) [ Time Frame: Maximum of 45 Months ]
    An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must be ≥ 18 years of age
  • Patients with histologically diagnosed relapsed high grade serous ovarian cancer (including primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer. Patients are eligible to undergo BRCA testing even if they have not yet had recurrence or progression of disease >6 months (>/=183 days) after completion of their last platinum therapy.
  • Documented germline mutation in Breast Cancer susceptibility genes: BRCA1 and/or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)
  • At least one lesion that can be accurately assessed at baseline by CT/MRI and is suitable for repeated assessment.
  • Patients must have received at least 2 prior platinum based lines of chemotherapy - Patients must be partially platinum sensitive or platinum sensitive
  • Patients must be suitable to start treatment with single agent chemotherapy based on physician's choice
  • Patients must have normal organ and bone marrow function measured within 28 days of randomisation,
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Patients must have a life expectancy ≥ 16 weeks
  • Formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer must be available for central testing.

Exclusion Criteria:

  • BRCA 1 and/or BRCA2 mutations that are considered to be non detrimental
  • Exposure to any investigational product within 30 days or 5 half lives (whichever is longer) prior to randomisation
  • Any previous treatment with a Polyadenosine 5'diphosphoribose polymerisation (PARP) inhibitor, including olaparib.
  • Patients who have platinum resistant or refractory disease
  • Patients receiving any systemic chemotherapy within 3 weeks prior to first dose of study treatment
  • Previous single agent exposure to the selected chemotherapy regimen for randomisation. - Prior malignancy in the last 5 years, unless curatively treated and recurrence free (few exceptions apply).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02282020


Locations
Hide Hide 78 study locations
Layout table for location information
United States, Alabama
Research Site
Birmingham, Alabama, United States, 35233
United States, California
Research Site
Sacramento, California, United States, 95817
Research Site
San Francisco, California, United States, 94118
United States, Colorado
Research Site
Aurora, Colorado, United States, 80045
Research Site
Littleton, Colorado, United States, 80120
United States, Connecticut
Research Site
Hartford, Connecticut, United States, 06106
United States, Georgia
Research Site
Augusta, Georgia, United States, 30912
United States, Louisiana
Research Site
Covington, Louisiana, United States, 70433
United States, Maryland
Research Site
Baltimore, Maryland, United States, 21204
United States, Michigan
Research Site
Detroit, Michigan, United States, 48201
United States, New York
Research Site
Albany, New York, United States, 12208
Research Site
Mineola, New York, United States, 11501
United States, North Carolina
Research Site
Chapel Hill, North Carolina, United States, 27599
United States, Ohio
Research Site
Columbus, Ohio, United States, 43210
United States, Oregon
Research Site
Springfield, Oregon, United States, 97477
United States, Pennsylvania
Research Site
Abington, Pennsylvania, United States, 19001
United States, Texas
Research Site
Bedford, Texas, United States, 76022
Research Site
Houston, Texas, United States, 77030
United States, Wisconsin
Research Site
Milwaukee, Wisconsin, United States, 53226
Argentina
Research Site
Caba, Argentina, 1280AEB
Research Site
Ciudad de Buenos Aires, Argentina, C1180AAX
Belgium
Research Site
Gent, Belgium, 9000
Research Site
Leuven, Belgium, 3000
Brazil
Research Site
Ijui, Brazil, 98700-000
Research Site
Passo Fundo, Brazil, 99010 260
Research Site
Porto Alegre, Brazil, 90035-003
Research Site
Porto Alegre, Brazil, 90610-000
Research Site
Rio de Janeiro, Brazil, 22793-080
Research Site
Sao Paulo, Brazil, 01246-000
Research Site
Sao Paulo, Brazil, 01317-000
Research Site
São José do Rio Preto, Brazil, 15090-000
Canada, Ontario
Research Site
Toronto, Ontario, Canada, M4N 3M5
Research Site
Toronto, Ontario, Canada, M5G 1X6
Canada, Quebec
Research Site
Montreal, Quebec, Canada, H2L 4M1
Czechia
Research Site
Hradec Kralove, Czechia, 500 05
Research Site
Ostrava-Poruba, Czechia, 708 53
Research Site
Praha 2, Czechia, 128 08
Research Site
Zlin, Czechia, 762 75
Hungary
Research Site
Budapest, Hungary, 1088
Research Site
Budapest, Hungary, 1115
Research Site
Budapest, Hungary, 1122
Research Site
Debrecen, Hungary, 4032
Research Site
Györ, Hungary, 9024
Israel
Research Site
Afula, Israel, 18101
Research Site
Haifa, Israel, 3109601
Research Site
Holon, Israel, 58100
Research Site
Kfar Saba, Israel, 44281
Research Site
Petah Tikva, Israel, 4941492
Research Site
Rehovot, Israel, 76100
Research Site
Tel-Aviv, Israel, 64239
Italy
Research Site
Meldola, Italy, 47014
Research Site
Milano, Italy, 20132
Research Site
Milano, Italy, 20133
Research Site
Milano, Italy, 20141
Research Site
Napoli, Italy, 80131
Research Site
Roma, Italy, 00144
Research Site
Roma, Italy, 00168
Korea, Republic of
Research Site
Goyang-si, Korea, Republic of, 10408
Research Site
Seoul, Korea, Republic of, 03080
Research Site
Seoul, Korea, Republic of, 05505
Research Site
Seoul, Korea, Republic of, 06273
Research Site
Seoul, Korea, Republic of, 06351
Research Site
Seoul, Korea, Republic of, 139-706
Mexico
Research Site
Mexico, Mexico, 6725
Research Site
Oaxaca, Mexico, 68000
Poland
Research Site
Gdańsk, Poland, 80-219
Research Site
Lublin, Poland, 20-090
Research Site
Olsztyn, Poland, 10-561
Research Site
Poznan, Poland, 60-569
Research Site
Warszawa, Poland, 02-781
Research Site
Łódź, Poland, 93-513
Spain
Research Site
Barcelona, Spain, 08035
Research Site
Barcelona, Spain, 08036
Research Site
Barcelona, Spain, 08907
Research Site
Córdoba, Spain, 14004
Research Site
Gerona, Spain, 17007
Research Site
Granada, Spain, 18014
Research Site
Madrid, Spain, 28050
Sponsors and Collaborators
AstraZeneca
Myriad Genetic Laboratories, Inc.
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Richard T Penson, Associate Prof. of Medicine Harvard Medical School
  Study Documents (Full-Text)

Documents provided by AstraZeneca:
Study Protocol  [PDF] December 20, 2017
Statistical Analysis Plan  [PDF] October 30, 2018


Additional Information:
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02282020    
Other Study ID Numbers: D0816C00010
First Posted: November 4, 2014    Key Record Dates
Results First Posted: December 2, 2019
Last Update Posted: December 2, 2019
Last Verified: November 2019
Keywords provided by AstraZeneca:
BRCA, ovarian, platinum, chemotherapy,
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carcinoma, Ovarian Epithelial
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Olaparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents